| 1 | Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections | Clinical Lymphoma, Myeloma and Leukemia | 2013 | 288 |
| 2 | Myeloid Sarcoma: Presentation, Diagnosis, and Treatment | Clinical Lymphoma, Myeloma and Leukemia | 2017 | 218 |
| 3 | Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia | Clinical Lymphoma, Myeloma and Leukemia | 2017 | 152 |
| 4 | Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm | Clinical Lymphoma, Myeloma and Leukemia | 2015 | 144 |
| 5 | Age, Race, Sex, Stage, and Incidence of Cutaneous Lymphoma | Clinical Lymphoma, Myeloma and Leukemia | 2012 | 132 |
| 6 | Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR | Clinical Lymphoma, Myeloma and Leukemia | 2020 | 132 |
| 7 | Nilotinib-Associated Vascular Events | Clinical Lymphoma, Myeloma and Leukemia | 2012 | 126 |
| 8 | Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval | Clinical Lymphoma, Myeloma and Leukemia | 2013 | 120 |
| 9 | Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis | Clinical Lymphoma, Myeloma and Leukemia | 2020 | 117 |
| 10 | An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma | Clinical Lymphoma, Myeloma and Leukemia | 2012 | 111 |
| 11 | Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial | Clinical Lymphoma, Myeloma and Leukemia | 2011 | 110 |
| 12 | Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia | Clinical Lymphoma, Myeloma and Leukemia | 2020 | 110 |
| 13 | Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma | Clinical Lymphoma, Myeloma and Leukemia | 2019 | 109 |
| 14 | HIV-Negative Plasmablastic Lymphoma: Not in the Mouth | Clinical Lymphoma, Myeloma and Leukemia | 2011 | 107 |
| 15 | Philadelphia Chromosome–like Acute Lymphoblastic Leukemia | Clinical Lymphoma, Myeloma and Leukemia | 2017 | 107 |
| 16 | Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma | Clinical Lymphoma, Myeloma and Leukemia | 2018 | 106 |
| 17 | Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment | Clinical Lymphoma, Myeloma and Leukemia | 2018 | 105 |
| 18 | Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1 | Clinical Lymphoma, Myeloma and Leukemia | 2015 | 104 |
| 19 | Treatment Options for Triple-class Refractory Multiple Myeloma | Clinical Lymphoma, Myeloma and Leukemia | 2020 | 104 |
| 20 | Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms | Clinical Lymphoma, Myeloma and Leukemia | 2014 | 101 |
| 21 | Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia | Clinical Lymphoma, Myeloma and Leukemia | 2011 | 100 |
| 22 | Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options | Clinical Lymphoma, Myeloma and Leukemia | 2013 | 98 |
| 23 | Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma | Clinical Lymphoma, Myeloma and Leukemia | 2020 | 97 |
| 24 | Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes | Clinical Lymphoma, Myeloma and Leukemia | 2017 | 92 |
| 25 | Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation | Clinical Lymphoma, Myeloma and Leukemia | 2015 | 90 |
| 26 | Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials | Clinical Lymphoma, Myeloma and Leukemia | 2017 | 89 |
| 27 | Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma | Clinical Lymphoma, Myeloma and Leukemia | 2014 | 88 |
| 28 | Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120 | Clinical Lymphoma, Myeloma and Leukemia | 2016 | 87 |
| 29 | Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel | Clinical Lymphoma, Myeloma and Leukemia | 2010 | 86 |
| 30 | Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | Clinical Lymphoma, Myeloma and Leukemia | 2013 | 85 |
| 31 | Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management | Clinical Lymphoma, Myeloma and Leukemia | 2017 | 84 |
| 32 | Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis | Clinical Lymphoma, Myeloma and Leukemia | 2010 | 83 |
| 33 | Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC) | Clinical Lymphoma, Myeloma and Leukemia | 2016 | 83 |
| 34 | Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma | Clinical Lymphoma, Myeloma and Leukemia | 2020 | 81 |
| 35 | Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I | Clinical Lymphoma, Myeloma and Leukemia | 2015 | 77 |
| 36 | Older Patients With Acute Myeloid Leukemia Benefit From Intensive Chemotherapy: An Update From the Swedish Acute Leukemia Registry | Clinical Lymphoma, Myeloma and Leukemia | 2011 | 76 |
| 37 | Accurate Machine-Learning-Based classification of Leukemia from Blood Smear Images | Clinical Lymphoma, Myeloma and Leukemia | 2021 | 76 |
| 38 | Beyond the CRAB Symptoms: A Study of Presenting Clinical Manifestations of Multiple Myeloma | Clinical Lymphoma, Myeloma and Leukemia | 2010 | 74 |
| 39 | A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Clinical Lymphoma, Myeloma and Leukemia | 2015 | 74 |
| 40 | Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma | Clinical Lymphoma, Myeloma and Leukemia | 2019 | 74 |
| 41 | Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome | Clinical Lymphoma, Myeloma and Leukemia | 2013 | 73 |
| 42 | Intensive Induction Chemotherapy Followed by Early High-Dose Therapy and Hematopoietic Stem Cell Transplantation Results in Improved Outcome for Patients with Hepatosplenic T-Cell Lymphoma: A Single Institution Experience | Clinical Lymphoma, Myeloma and Leukemia | 2013 | 73 |
| 43 | A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients | Clinical Lymphoma, Myeloma and Leukemia | 2015 | 73 |
| 44 | Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations | Clinical Lymphoma, Myeloma and Leukemia | 2012 | 72 |
| 45 | Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study | Clinical Lymphoma, Myeloma and Leukemia | 2018 | 72 |
| 46 | Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma | Clinical Lymphoma, Myeloma and Leukemia | 2018 | 72 |
| 47 | Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States | Clinical Lymphoma, Myeloma and Leukemia | 2011 | 71 |
| 48 | Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study | Clinical Lymphoma, Myeloma and Leukemia | 2016 | 69 |
| 49 | CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia | Clinical Lymphoma, Myeloma and Leukemia | 2011 | 68 |
| 50 | Low Venous Thromboembolic Risk With Bortezomib in Multiple Myeloma and Potential Protective Effect With Thalidomide/Lenalidomide-based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens | Clinical Lymphoma, Myeloma and Leukemia | 2011 | 67 |
